Literature DB >> 26912618

APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

John F Krisko1, Nurjahan Begum1, Caroline E Baker1, John L Foster2, J Victor Garcia2.   

Abstract

UNLABELLED: The multifunctional HIV-1 accessory protein Vif counters the antiviral activities of APOBEC3G (A3G) and APOBEC3F (A3F), and some Vifs counter stable alleles of APOBEC3H (A3H). Studies in humanized mice have shown that HIV-1 lacking Vif expression is not viable. Here, we look at the relative contributions of the three APOBEC3s to viral extinction. Inoculation of bone marrow/liver/thymus (BLT) mice with CCR5-tropic HIV-1JRCSF(JRCSF) expressing a vif gene inactive for A3G but not A3F degradation activity (JRCSFvifH42/43D) displayed either no or delayed replication. JRCSF expressing a vif gene mutated to inactivate A3F degradation but not A3G degradation (JRCSFvifW79S) always replicated to high viral loads with variable delays. JRCSF with vif mutated to lack both A3G and A3F degradation activities (JRCSFvifH42/43DW79S) failed to replicate, mimicking JRCSF without Vif expression (JRCSFΔvif). JRCSF and JRCSFvifH42/43D, but not JRCSFvifW79S or JRCSFvifH42/43DW79S, degraded APOBEC3D. With one exception, JRCSFs expressing mutant Vifs that replicated acquired enforced vif mutations. These mutations partially restored A3G or A3F degradation activity and fully replaced JRCSFvifH42/43D or JRCSFvifW79S by 10 weeks. Surprisingly, induced mutations temporally lagged behind high levels of virus in blood. In the exceptional case, JRCSFvifH42/43D replicated after a prolonged delay with no mutations in vif but instead a V27I mutation in the RNase H coding sequence. JRCSFvifH42/43D infections exhibited massive GG/AG mutations in pol viral DNA, but in viral RNA, there were no fixed mutations in the Gag or reverse transcriptase coding sequence. A3H did not contribute to viral extinction but, in combination with A3F, could delay JRCSF replication. A3H was also found to hypermutate viral DNA. IMPORTANCE: Vif degradation of A3G and A3F enhances viral fitness, as virus with even a partially restored capacity for degradation outgrows JRCSFvifH42/43D and JRCSFvifW79S. Unexpectedly, fixation of mutations that replaced H42/43D or W79S in viral RNA lagged behind the appearance of high viral loads. In one exceptional JRCSFvifH42/43D infection, vif was unchanged but replication proceeded after a long delay. These results suggest that Vif binds and inhibits the non-cytosine deaminase activities of intact A3G and intact A3F, allowing JRCSFvifH42/43D and JRCSFvifW79S to replicate with reduced fitness. Subsequently, enhanced Vif function is acquired by enforced mutations. In infected cells, JRCSFΔvif and JRCSFvifH42/43DW79S are exposed to active A3F and A3G and fail to replicate. JRCSFvifH42/43D Vif degrades A3F and, in some cases, overcomes A3G mutagenic activity to replicate. Vif may have evolved to inhibit A3F and A3G by stoichiometric binding and subsequently acquired the ability to target these proteins to proteasomes.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26912618      PMCID: PMC4836340          DOI: 10.1128/JVI.03275-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.

Authors:  Tamiko Nagao; Tomoki Yamashita; Ariko Miyake; Tsuneo Uchiyama; Masako Nomaguchi; Akio Adachi
Journal:  J Med Invest       Date:  2010-02

2.  APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.

Authors:  Jean L Mbisa; Wei Bu; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

3.  Multifaceted counter-APOBEC3G mechanisms employed by HIV-1 Vif.

Authors:  Elena Britan-Rosich; Roni Nowarski; Moshe Kotler
Journal:  J Mol Biol       Date:  2011-07-29       Impact factor: 5.469

4.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

Review 7.  Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Authors:  John S Albin; Reuben S Harris
Journal:  Expert Rev Mol Med       Date:  2010-01-22       Impact factor: 5.600

8.  HIV-1 Vif adaptation to human APOBEC3H haplotypes.

Authors:  Marcel Ooms; Bonnie Brayton; Michael Letko; Susan M Maio; Christopher D Pilcher; Frederick M Hecht; Jason D Barbour; Viviana Simon
Journal:  Cell Host Microbe       Date:  2013-10-16       Impact factor: 21.023

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif.

Authors:  Marcel Ooms; Michael Letko; Mawuena Binka; Viviana Simon
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more
  13 in total

1.  An Alu Element Insertion in Intron 1 Results in Aberrant Alternative Splicing of APOBEC3G Pre-mRNA in Northern Pig-Tailed Macaques (Macaca leonina) That May Reduce APOBEC3G-Mediated Hypermutation Pressure on HIV-1.

Authors:  Xiao-Liang Zhang; Meng-Ting Luo; Jia-Hao Song; Wei Pang; Yong-Tang Zheng
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

2.  Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.

Authors:  Anjuman Ara; Robin P Love; Tyson B Follack; Khawaja A Ahmed; Madison B Adolph; Linda Chelico
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

3.  Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice.

Authors:  Matthew M Hernandez; Audrey Fahrny; Ravi Sachidanandam; Roberto F Speck; Viviana Simon; Anitha Jayaprakash; Gustavo Gers-Huber; Marsha Dillon-White; Annette Audigé; Lubbertus C F Mulder
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

4.  The Structural Interface between HIV-1 Vif and Human APOBEC3H.

Authors:  Marcel Ooms; Michael Letko; Viviana Simon
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

5.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

6.  Molecular Biology and Diversification of Human Retroviruses.

Authors:  Morgan E Meissner; Nathaniel Talledge; Louis M Mansky
Journal:  Front Virol       Date:  2022-06-02

7.  Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection.

Authors:  Ousman Jobe; Jiae Kim; Eric Tycksen; Sayali Onkar; Nelson L Michael; Carl R Alving; Mangala Rao
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

Review 8.  A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif.

Authors:  Yusuke Nakano; Hirofumi Aso; Andrew Soper; Eri Yamada; Miyu Moriwaki; Guillermo Juarez-Fernandez; Yoshio Koyanagi; Kei Sato
Journal:  Retrovirology       Date:  2017-05-08       Impact factor: 4.602

9.  HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.

Authors:  Yusuke Nakano; Naoko Misawa; Guillermo Juarez-Fernandez; Miyu Moriwaki; Shinji Nakaoka; Takaaki Funo; Eri Yamada; Andrew Soper; Rokusuke Yoshikawa; Diako Ebrahimi; Yuuya Tachiki; Shingo Iwami; Reuben S Harris; Yoshio Koyanagi; Kei Sato
Journal:  PLoS Pathog       Date:  2017-05-05       Impact factor: 6.823

10.  Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants.

Authors:  Chiara E Cotroneo; Nunzia Mangano; Tommaso A Dragani; Francesca Colombo
Journal:  Eur J Hum Genet       Date:  2021-03-01       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.